CN113072564A - Heteroaromatic ring compound and application thereof - Google Patents
Heteroaromatic ring compound and application thereof Download PDFInfo
- Publication number
- CN113072564A CN113072564A CN202110307268.XA CN202110307268A CN113072564A CN 113072564 A CN113072564 A CN 113072564A CN 202110307268 A CN202110307268 A CN 202110307268A CN 113072564 A CN113072564 A CN 113072564A
- Authority
- CN
- China
- Prior art keywords
- substituted
- unsubstituted
- compound
- ring
- carbon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 176
- 125000001072 heteroaryl group Chemical group 0.000 title claims abstract description 28
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 25
- 230000003115 biocidal effect Effects 0.000 claims abstract description 25
- 150000003839 salts Chemical class 0.000 claims abstract description 22
- 241000894006 Bacteria Species 0.000 claims abstract description 19
- 230000003287 optical effect Effects 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims description 40
- 238000002360 preparation method Methods 0.000 claims description 30
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 claims description 28
- 239000003242 anti bacterial agent Substances 0.000 claims description 27
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 24
- -1 hydroxy, mercapto, amino Chemical group 0.000 claims description 24
- 229960001180 norfloxacin Drugs 0.000 claims description 21
- 229910052736 halogen Inorganic materials 0.000 claims description 19
- 150000002367 halogens Chemical class 0.000 claims description 19
- 229940088710 antibiotic agent Drugs 0.000 claims description 18
- 241000191967 Staphylococcus aureus Species 0.000 claims description 17
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 17
- 125000003118 aryl group Chemical group 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 11
- 125000005842 heteroatom Chemical group 0.000 claims description 10
- 125000000623 heterocyclic group Chemical group 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 125000001424 substituent group Chemical group 0.000 claims description 9
- 125000006707 (C3-C12) heterocycloalkyl group Chemical group 0.000 claims description 8
- 125000004414 alkyl thio group Chemical group 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 7
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims description 7
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 6
- 125000002947 alkylene group Chemical group 0.000 claims description 6
- 230000002708 enhancing effect Effects 0.000 claims description 6
- 125000001188 haloalkyl group Chemical group 0.000 claims description 6
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 125000005347 halocycloalkyl group Chemical group 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 4
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 3
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 claims description 3
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 2
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 2
- 206010059866 Drug resistance Diseases 0.000 abstract description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 129
- 238000004949 mass spectrometry Methods 0.000 description 88
- 239000000243 solution Substances 0.000 description 58
- 239000011541 reaction mixture Substances 0.000 description 44
- 239000007787 solid Substances 0.000 description 42
- 238000003786 synthesis reaction Methods 0.000 description 32
- 230000015572 biosynthetic process Effects 0.000 description 31
- 239000000203 mixture Substances 0.000 description 31
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
- 239000007832 Na2SO4 Substances 0.000 description 29
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 29
- 239000012267 brine Substances 0.000 description 29
- 239000012044 organic layer Substances 0.000 description 29
- 229910052938 sodium sulfate Inorganic materials 0.000 description 29
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- 229940079593 drug Drugs 0.000 description 26
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- 239000003306 quinoline derived antiinfective agent Substances 0.000 description 21
- 238000010898 silica gel chromatography Methods 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- KYGZCKSPAKDVKC-UHFFFAOYSA-N Oxolinic acid Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC2=C1OCO2 KYGZCKSPAKDVKC-UHFFFAOYSA-N 0.000 description 15
- 125000000217 alkyl group Chemical group 0.000 description 15
- 125000000753 cycloalkyl group Chemical group 0.000 description 15
- 238000002347 injection Methods 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 13
- 239000003208 petroleum Substances 0.000 description 13
- 238000000034 method Methods 0.000 description 12
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 10
- 125000004432 carbon atom Chemical group C* 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 239000002552 dosage form Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000007821 HATU Substances 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 229940125782 compound 2 Drugs 0.000 description 6
- 229940126214 compound 3 Drugs 0.000 description 6
- 229940125898 compound 5 Drugs 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- 241000191940 Staphylococcus Species 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 150000001721 carbon Chemical group 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000192125 Firmicutes Species 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 230000000845 anti-microbial effect Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 125000002993 cycloalkylene group Chemical group 0.000 description 4
- 239000010408 film Substances 0.000 description 4
- 239000004005 microsphere Substances 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 239000006072 paste Substances 0.000 description 4
- 125000003367 polycyclic group Chemical group 0.000 description 4
- 125000006413 ring segment Chemical group 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 3
- WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 3
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000003978 infusion fluid Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 125000004193 piperazinyl group Chemical group 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 125000006584 (C3-C10) heterocycloalkyl group Chemical group 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
- ZEEBGORNQSEQBE-UHFFFAOYSA-N [2-(3-phenylphenoxy)-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound C1(=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)C1=CC=CC=C1 ZEEBGORNQSEQBE-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- OGEBRHQLRGFBNV-RZDIXWSQSA-N chembl2036808 Chemical group C12=NC(NCCCC)=NC=C2C(C=2C=CC(F)=CC=2)=NN1C[C@H]1CC[C@H](N)CC1 OGEBRHQLRGFBNV-RZDIXWSQSA-N 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000003113 dilution method Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 description 2
- 125000002636 imidazolinyl group Chemical group 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- 125000006589 (C3-C10) heterocycloalkylene group Chemical group 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- UVNPEUJXKZFWSJ-LMTQTHQJSA-N (R)-N-[(4S)-8-[6-amino-5-[(3,3-difluoro-2-oxo-1H-pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]pyrazin-2-yl]-2-oxa-8-azaspiro[4.5]decan-4-yl]-2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](=O)N[C@@H]1COCC11CCN(CC1)c1cnc(Sc2ccnc3NC(=O)C(F)(F)c23)c(N)n1 UVNPEUJXKZFWSJ-LMTQTHQJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical group C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- IJVFHCSUEBAAOZ-UHFFFAOYSA-N 3-fluoro-2-nitropyridine Chemical compound [O-][N+](=O)C1=NC=CC=C1F IJVFHCSUEBAAOZ-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 1
- 125000004406 C3-C8 cycloalkylene group Chemical group 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000003810 Jones reagent Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- NUGPIZCTELGDOS-QHCPKHFHSA-N N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclopentanecarboxamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CC[C@@H](C=1C=NC=CC=1)NC(=O)C1CCCC1)C NUGPIZCTELGDOS-QHCPKHFHSA-N 0.000 description 1
- 229910017852 NH2NH2 Inorganic materials 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229910019020 PtO2 Inorganic materials 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 150000001555 benzenes Chemical group 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004976 cyclobutylene group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004977 cycloheptylene group Chemical group 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004979 cyclopentylene group Chemical group 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004980 cyclopropylene group Chemical group 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 150000002473 indoazoles Chemical group 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- CZBVTGOJEKVWBB-UHFFFAOYSA-N methyl 3-fluoropyridine-2-carboxylate Chemical compound COC(=O)C1=NC=CC=C1F CZBVTGOJEKVWBB-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical group C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- AMWSEGBTTPQUKW-SSDOTTSWSA-N tert-butyl n-[(2r)-but-3-yn-2-yl]carbamate Chemical compound C#C[C@@H](C)NC(=O)OC(C)(C)C AMWSEGBTTPQUKW-SSDOTTSWSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a heteroaromatic ring compound and application thereof. Specifically, the invention provides a compound shown in formula I, or an optical isomer or racemate thereof, or a pharmaceutically acceptable salt thereof. The compound of the invention can obviously enhance the antibacterial effect of antibioticsThereby reducing the dosage of the antibiotic and reducing the generation of the drug resistance of the bacteria.
Description
Technical Field
The invention relates to the field of medicines, in particular to a heteroaromatic ring compound and application thereof.
Background
Antibiotic resistance is considered to be the greatest threat in the treatment of infectious diseases, as antibiotic abuse in clinical and non-clinical situations leads to reduced antibiotic activity of antibiotics, and drug-resistant bacteria appear, and infections caused by drug-resistant bacteria are becoming more serious.
With the emergence of drug-resistant bacteria, the inhibition effect of antibiotics on the drug-resistant bacteria is weakened, and for this reason, the infection of the drug-resistant bacteria is often controlled by increasing the dosage of antibiotics in clinic, however, increasing the dosage of antibiotics not only leads to the increase of medical cost and side effects of antibiotics, but also further leads to the emergence of stronger drug-resistant bacteria, and therefore, increasing the dosage of antibiotics cannot achieve ideal antibacterial treatment effect. How to improve the bacteriostatic effect of antibiotics becomes a hot point of current research.
Therefore, there is a need in the art to develop a drug capable of improving the bactericidal effect of an antibiotic, thereby improving the therapeutic effect of the antibiotic.
Disclosure of Invention
The invention aims to provide a medicament capable of improving the sterilization effect of antibiotics, thereby improving the treatment effect of the antibiotics.
In a first aspect the present invention provides a compound of formula I, or an optical isomer or racemate thereof, or a pharmaceutically acceptable salt thereof;
wherein the content of the first and second substances,
ring A is a substituted or unsubstituted C3-C12 cycloalkane ring, a substituted or unsubstituted C6-C16 aromatic ring, a substituted or unsubstituted 3-16 membered heteroaromatic ring, or a substituted or unsubstituted 3-12 membered heterocycloalkyl ring;
ring B is a substituted or unsubstituted C3-C12 cycloalkane ring, a substituted or unsubstituted C6-C16 aromatic ring, a substituted or unsubstituted 3-16 membered heteroaromatic ring, or a substituted or unsubstituted 3-12 membered heterocycloalkyl ring;
Z1is-O-, -S-, substituted or unsubstituted C3-C12 cycloalkylene, substituted or unsubstituted 3-12 membered heterocycloalkylene, or substituted or unsubstituted C1-C6 alkyl-N (R)5)-;
when in useWhen it is a carbon-carbon single bond, Z2is-C (O) -NH-, substituted or unsubstituted C1-C8 alkylene, -O-, -S-; or whenWhen it is a carbon-carbon double bond, Z2is-CH ═ or-R6-CH=;
R1、R2、R3And R4Each independently hydrogen, substituted or unsubstituted C1-C8 alkyl, substituted or unsubstituted C3-C12 cycloalkyl, or substituted or unsubstituted 3-12 membered heterocycloalkyl;
R5is hydrogen, substituted or unsubstituted C1-C6 alkyl, or substituted or unsubstituted C3-C8 cycloalkyl;
R6is a substituted or unsubstituted C1-C6 alkylene group;
wherein any "substitution" means that one or more (preferably 1, 2, 3, 4 or 5) hydrogen atoms on the group are substituted with a substituent selected from the group consisting of: C1-C8 alkyl, C3-C8 cycloalkyl, C1-C8 haloalkyl, C3-C8 halocycloalkyl, halogen, hydroxy, mercapto, amino, C1-C8 alkoxy, C1-C8 alkylthio, C6-C12 aryl, 5-10 membered heteroaryl, 5-10 membered heterocycloalkyl;
the heterocyclic rings of the heteroaryl ring, heterocycloalkyl ring, heteroaryl group and heterocycloalkyl group each independently have 1-4 (preferably 1, 2, 3 or 4) heteroatoms selected from N, O and S.
Preferably, Ring A is a substituted or unsubstituted C3-C12 cycloalkane ring, a substituted or unsubstituted C6-C12 aromatic ring, a substituted or unsubstituted 3-12 membered heteroaromatic ring, or a substituted or unsubstituted 3-12 membered heterocycloalkyl ring.
Preferably, ring a is a substituted or unsubstituted indazole ring, or a substituted or unsubstituted pyrazolopyrimidine ring.
Preferably, the indazole ring is a 1H-indazole ring.
Preferably, the pyrazolopyrimidine ring is a pyrazolo [1, 5-alpha ] pyrimidine ring.
Preferably, Ring B is a substituted or unsubstituted C3-C12 cycloalkane ring, a substituted or unsubstituted C6-C12 aromatic ring, a substituted or unsubstituted 3-12 membered heteroaromatic ring, or a substituted or unsubstituted 3-12 membered heterocycloalkyl ring.
Preferably, ring B is a substituted or unsubstituted C3-C10 cycloalkane ring, a substituted or unsubstituted C6-C10 aromatic ring, a substituted or unsubstituted 3-10 membered heteroaromatic ring, or a substituted or unsubstituted 3-10 membered heterocycloalkyl ring.
Preferably, ring B is a substituted or unsubstituted C5-C8 cycloalkane ring, a substituted or unsubstituted C6-C8 aromatic ring, a substituted or unsubstituted 5-8 membered heteroaromatic ring, or a substituted or unsubstituted 5-8 membered heterocycloalkyl ring.
Preferably, ring B is a substituted or unsubstituted C6, C7, C8, C5, C6, C7, or C8 heteroaromatic ring.
Preferably, ring B is a substituted or unsubstituted benzene ring or a substituted or unsubstituted pyridine ring.
Preferably, ring B is substituted or unsubstitutedSubstituted or unsubstitutedOr substituted or unsubstituted
Preferably, R7 is halogen.
Preferably, the halogen is F, Cl, Br or I.
Preferably, Z1is-O-, -S-, substituted or unsubstituted C3-C10 cycloalkylene, substituted or unsubstituted 3-10 membered heterocycloalkylene, or substituted or unsubstituted C1-C6 alkyl-N (R)5)-。
Preferably, Z1is-O-, -S-, substituted or unsubstituted C3-C8 cycloalkylene, substituted or unsubstituted 3-8 membered heterocycloalkylene, or substituted or unsubstituted C1-C4 alkyl-N (R)5)-。
Preferably, Z1is-O-, -S-, substituted or unsubstituted C5-C8 cycloalkylene, substituted or unsubstituted 5-8 membered heterocycloalkylene, or substituted or unsubstituted C1-C4 alkyl-N (R)5)-。
Preferably, Z1is-O-, -S-, substituted or unsubstituted tetrahydropyrrolylene, or-methyl-N (R)5)-。
Preferably, R5Is hydrogen, substituted or unsubstituted C1-C4 alkyl, or substituted or unsubstituted C3-C6 cycloalkyl.
Preferably, R5Is hydrogen, methyl, ethyl, propyl, or butyl.
Preferably, Z1The heteroatom of the substituent is attached to the A ring.
Preferably, whenWhen it is a carbon-carbon single bond, Z2is-C (O) -NH-, substituted or unsubstituted C1-C4 alkylene, -O-, or-S-.
Preferably, whenWhen it is a carbon-carbon single bond, Z2is-C (O) -NH-, methylene, ethylene, propylene, butylene, -O-, or-S-.
Preferably, R6Is a substituted or unsubstituted C1-C4 alkylene.
Preferably, R6Is methylene, ethylene, propylene, or butylene.
Preferably, R1、R2、R3And R4Each independently hydrogen, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C10 cycloalkyl, or substituted or unsubstituted 3-10 membered heterocycloalkyl.
Preferably, R1、R2、R3And R4Each independently hydrogen, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C3-C8 cycloalkyl, or substituted or unsubstituted 3-8 membered heterocycloalkyl.
Preferably, R1、R2、R3And R4Each independently hydrogen, methyl, ethyl, propyl, or butyl.
Preferably, any "substitution" means that one or more (preferably 1, 2, 3, 4 or 5) hydrogen atoms on the group are substituted with a substituent selected from the group consisting of: C1-C4 alkyl, C3-C8 cycloalkyl, C1-C4 haloalkyl, C3-C8 halocycloalkyl, halogen, hydroxy, mercapto, amino, C1-C4 alkoxy, C1-C4 alkylthio, C6-C8 aryl, 5-8 membered heteroaryl, 5-8 membered heterocycloalkyl.
Preferably, the heterocyclic rings of the heteroaryl ring, heterocycloalkyl ring, heteroaryl, heterocycloalkyl group and heterocycloalkylene group each independently have 1 to 4 (preferably 1, 2, 3 or 4) heteroatoms selected from N, O and S.
Preferably, the compound of formula I has the structure described by formula I-1:
wherein the content of the first and second substances,
Z1、Z2、R1、R2、R3and R4As defined above;
w is CH or N.
Preferably, the compound of formula I has the structure depicted in formula I-2:
wherein the content of the first and second substances,
Z1、Z2、R1、R2、R3and R4As defined above;
w is CH or N;
R8is halogen.
Preferably, the compound of formula I has the structure depicted in formula I-3:
wherein R is1、R2、R3、R4And R5As defined above;
w is CH or N;
R8is halogen.
Preferably, the compound of formula I has the structure depicted in formula I-4:
wherein R is1、R3、R4And R5As defined above;
w is CH or N;
R8is halogen.
Preferably, the compound of formula I has the structure depicted in formula I-5:
wherein R is1、R3And R4As defined above;
w is CH or N;
R8is halogen.
Preferably, the compound of formula I has the structure depicted in formula I-6:
wherein R is1、R3And R4As defined above;
w is CH or N;
R8is halogen.
Preferably, the compound of formula I has the structure described in formula I-7:
wherein R is1、R2、R3And R4As defined above;
w is CH or N;
R8is halogen.
Preferably, the compound of formula I is:
in a second aspect of the invention, there is provided the use of a compound of formula I, as described in the first aspect of the invention, or an optical isomer or racemate thereof, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for enhancing the antibacterial effectiveness of an antibiotic.
Preferably, the antibiotic is a quinolone antibiotic.
Preferably, the quinolone antibiotic is a fluoroquinolone antibiotic.
Preferably, said quinolone antibiotic comprises norfloxacin.
Preferably, the antimicrobial comprises antibacterial.
Preferably, the bacteria comprise drug-resistant bacteria.
Preferably, the bacteria comprise gram positive bacteria.
Preferably, the gram-positive bacterium comprises a staphylococcus.
Preferably, the staphylococcus includes a staphylococcus aureus strain.
Preferably, the staphylococcus aureus strain comprises a multidrug resistant staphylococcus aureus strain SA-1199B containing a NorA efflux pump resistance gene.
Preferably, the antibiotic comprises an antibiotic comprising multidrug resistant Staphylococcus aureus strain SA-1199B containing a NorA efflux pump resistance gene.
Preferably, the dosage form of the medicament is a solid preparation, a liquid preparation or a semisolid preparation.
Preferably, the medicament is in the form of oral preparation, external preparation or injection preparation
Preferably, the dosage form of the medicine is tablets, injections, infusion solutions, pastes, gels, solutions, microspheres or films.
In a third aspect of the present invention, there is provided a pharmaceutical composition comprising a compound of formula I as described in the first aspect of the present invention, or an optical isomer or racemate thereof, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
Preferably, the pharmaceutical composition further comprises an antibiotic.
Preferably, the antibiotic comprises a quinolone antibiotic.
Preferably, the quinolone antibiotic is a fluoroquinolone antibiotic.
Preferably, said quinolone antibiotic comprises norfloxacin.
Preferably, the dosage form of the pharmaceutical composition is a solid preparation, a liquid preparation or a semisolid preparation.
Preferably, the dosage form of the pharmaceutical composition is oral preparation, external preparation or injection preparation
Preferably, the dosage form of the pharmaceutical composition is tablets, injections, infusion solutions, pastes, gels, solutions, microspheres or films.
In a fourth aspect of the present invention, there is provided an active ingredient combination comprising a compound of formula I as described in the first aspect of the present invention, or an optical isomer or racemate thereof, or a pharmaceutically acceptable salt thereof; and antibiotics.
Preferably, the antibiotic comprises a quinolone antibiotic.
Preferably, the quinolone antibiotic is a fluoroquinolone antibiotic.
Preferably, said quinolone antibiotic comprises norfloxacin.
In a fifth aspect of the invention, there is provided a use of a pharmaceutical composition according to the third aspect of the invention or an active ingredient combination according to the fourth aspect of the invention for the manufacture of an antibacterial medicament.
Preferably, the antimicrobial comprises antibacterial.
Preferably, the bacteria comprise drug-resistant bacteria.
Preferably, the bacteria comprise gram positive bacteria.
Preferably, the gram-positive bacterium comprises a staphylococcus.
Preferably, the staphylococcus includes a staphylococcus aureus strain.
Preferably, the staphylococcus aureus strain comprises a multidrug resistant staphylococcus aureus strain SA-1199B containing a NorA efflux pump resistance gene.
Preferably, the antibiotic comprises an antibiotic comprising multidrug resistant Staphylococcus aureus strain SA-1199B containing a NorA efflux pump resistance gene.
Preferably, the dosage form of the medicament is a solid preparation, a liquid preparation or a semisolid preparation.
Preferably, the medicament is in the form of oral preparation, external preparation or injection preparation
Preferably, the dosage form of the medicine is tablets, injections, infusion solutions, pastes, gels, solutions, microspheres or films.
In a sixth aspect of the present invention, there is provided a method for enhancing the antibacterial efficacy of an antibiotic, said method comprising the steps of: administering to a subject in need thereof a compound of formula I as described in the first aspect of the invention, or an optical isomer or racemate thereof, or a pharmaceutically acceptable salt thereof, thereby enhancing the antibacterial efficacy of the antibiotic.
Preferably, the subject comprises a human or non-human mammal.
In a seventh aspect of the present invention, there is provided a method for antibacterial, the method comprising the steps of: administering to a subject in need thereof a combination of active ingredients according to the fourth aspect of the invention for antibacterial use.
Preferably, the subject comprises a human or non-human mammal.
It is to be understood that within the scope of the present invention, the above-described features of the present invention and those specifically described below (e.g., in the examples) may be combined with each other to form new or preferred embodiments.
Detailed Description
The invention develops a compound with a novel structure, which can remarkably enhance the antibacterial effect of antibiotics, thereby reducing the dosage of the antibiotics and reducing the generation of bacterial drug resistance.
Term(s) for
As used herein, the terms "comprising," including, "and" containing "are used interchangeably and include not only open-ended definitions, but also semi-closed and closed-ended definitions, and include" consisting of … …, "" consisting essentially of … ….
As used herein, the term "alkyl" refers to a straight-chain (i.e., unbranched) or branched-chain saturated hydrocarbon group containing only carbon atoms, or a combination of straight-chain and branched-chain groups. When an alkyl group is preceded by a carbon atom number limitation, such as C1-C6 alkyl means that the alkyl group contains 1-6 carbon atoms, representative examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, or the like.
As used herein, the term "alkylene" refers to a group formed by the removal of one hydrogen atom from an alkyl group, as defined above. Representative examples of alkylene groups include, but are not limited to, methylene, ethylene, propylene, isopropylene, butylene, or the like.
In the present invention, the term "halogen" means F, Cl, Br or I.
In the present invention, the term "halo" means substituted by halogen.
As used herein, the term "haloalkyl" means an alkyl group wherein one or more (preferably 1, 2, 3 or 4) hydrogens are replaced with a halogen, said alkyl and halogen being as defined above, when the alkyl group previously has a carbon atom number limitation (e.g., C1-C8 haloalkyl) means that said alkyl group contains 1-8 carbon atoms, representative examples of haloalkyl include, but are not limited to, -CF3、-CHF2Or the like.
As used herein, the term "cycloalkane ring" refers to a monocyclic, bicyclic or polycyclic (fused, bridged or spiro) ring system having a saturated or partially saturated unit ring. When a certain cycloalkane ring is preceded by a carbon atom number limitation (e.g., C3-C12), it means that the cycloalkane ring has from 3 to 12 ring carbon atoms. Representative examples of cycloalkane rings include, but are not limited to, cyclopropane, cyclobutane, cyclopentane, cycloheptane, or the like.
As used herein, the term "cycloalkyl" refers to a group formed by the removal of one hydrogen atom from a cycloalkane ring, as defined above. Representative examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cycloheptyl, or similar rings.
As used herein, the term "cycloalkylene" refers to a radical formed by removing one hydrogen atom from a cycloalkyl group, which is as defined above. Representative examples of cycloalkylene groups include, but are not limited to, cyclopropylene, cyclobutylene, cyclopentylene, cycloheptylene, or similar rings.
As used herein, the term "halocycloalkyl" means a cycloalkyl group wherein one or more (preferably 1, 2, 3 or 4) hydrogens are replaced with a halogen, said cycloalkyl and halogen being as defined above, when the cycloalkyl group previously has a carbon atom number limitation (e.g., C3-C8 haloalkyl) means that said cycloalkyl group contains from 3 to 8 ring carbon atoms. Representative examples of halocycloalkyl groups include, but are not limited to, monofluorocyclopropyl, monochlorocyclobutyl, monofluorocyclopentyl, or the like.
The term "alkoxy" refers to the group R-O-, wherein R is alkyl, alkyl is as defined herein, when alkoxy is previously defined by the number of carbon atoms, e.g., C1-C8 alkoxy means that the alkyl in said alkoxy has 1-8 carbon atoms. Representative examples of alkoxy groups include, but are not limited to: methoxy, ethoxy, n-propoxy, isopropoxy, tert-butoxy, or the like.
As used herein, the term "alkylthio" refers to the group R-O-wherein R is alkyl and alkyl is as defined herein above, when an alkylthio group is previously defined as having a carbon number, e.g., C1-C8 alkylthio means that the alkyl group in the alkylthio group has from 1 to 8 carbon atoms. Representative examples of alkylthio groups include, but are not limited to: methylthio, ethylthio, n-propylthio, isopropylthio, tert-butylthio, or the like.
The term "heterocycloalkyl ring" refers to a fully saturated or partially unsaturated ring (including but not limited to, e.g., 3-7 membered monocyclic, 7-11 membered bicyclic) in which at least one heteroatom is present in the ring having at least one carbon atom. When the heterocyclic ring is preceded by a defined number of members, this refers to the number of ring atoms of the heterocyclic ring, for example, a 3-12 membered heterocyclic ring refers to a heterocyclic ring having 3-12 ring atoms. Each heteroatom-containing heterocycle may carry one or more (e.g. 1, 2, 3 or 4) heteroatoms each independently selected from nitrogen, oxygen or sulfur atoms. Representative examples of heterocycloalkyl rings include, but are not limited to: oxetane, imidazoline ring, imidazolidine ring, tetrahydrofuran ring, piperidine ring, piperazine ring, or the like.
The term "heterocycloalkyl" refers to a group formed by the removal of one hydrogen atom from a heterocycloalkyl ring, which is defined above. Representative examples of heterocycloalkyl groups include, but are not limited to, azetidinyl, imidazolinyl, imidazolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, tetrahydropyranyl, or the like.
As used herein, the term "heterocycloalkylene" refers to a group formed by removing one hydrogen atom from a heterocycloalkyl group, which is defined above. Representative examples of heterocycloalkylene groups include, but are not limited to, azetidinylene, imidazolinylene, imidazolidinylene, tetrahydrofurylene, piperidylene, piperazinyl, tetrahydropyranyl, or the like.
The term "aromatic ring" refers to an all-carbon monocyclic or fused polycyclic ring (i.e., rings which share adjacent pairs of carbon atoms) having a conjugated pi-electron system, and is an aromatic cyclic hydrocarbon compound, when an aromatic ring has a carbon number limitation as in the preceding, e.g., C6-C12, aromatic rings, meaning that the aromatic ring has 6 to 12 ring carbon atoms. Representative examples of aromatic rings include, but are not limited to: a benzene ring, a naphthalene ring, or the like.
The term "aryl" refers to a group formed by the removal of one hydrogen atom from an aromatic ring, as defined above. Representative examples of aryl groups include, but are not limited to: phenyl, naphthyl, or the like.
The term "heteroaromatic ring" refers to an aromatic heterocyclic ring having one to more (preferably 1, 2, 3 or 4) heteroatoms, which may be monocyclic (monocyclic) or polycyclic (bicyclic, tricyclic or polycyclic) fused together or covalently linked, and which may have one or more (e.g., 1, 2, 3, 4) heteroatoms per heteroatom-containing heterocyclic ring independently selected from the group consisting of: oxygen, sulfur and nitrogen. When a heteroaryl ring is preceded by a number of members, this refers to the number of ring atoms of the heteroaryl ring, for example, a 5-12 membered heteroaryl ring refers to a heteroaryl ring having 5-12 ring atoms. Representative examples of heteroaryl rings include, but are not limited to: a pyrrole ring, a pyrazole ring, an imidazole ring, an oxazole ring, a thiazole ring, a furan ring, a pyridine ring, a pyrazine ring, a pyrimidine ring, a pyridazine ring, a triazazole ring, a tetrazenazole ring, or the like.
The term "heteroaryl" refers to a group formed by the removal of one hydrogen atom from a heteroaromatic ring, as defined above. Representative examples of aryl groups include, but are not limited to: pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, furanyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, triazolyl, tetrazolyl, or the like.
In this specification, it is to be construed that all substituents are unsubstituted, unless expressly described as "substituted" herein. The term "substituted" means that one or more hydrogen atoms on a particular group are replaced with a particular substituent. Particular substituents are those described correspondingly in the foregoing, or as appearing in the examples. Unless otherwise specified, an optionally substituted group may have a substituent selected from a specific group at any substitutable site of the group, and the substituents may be the same or different at each position.
Active ingredient
As used herein, "a compound of the invention", "a compound of formula I of the invention", or "a compound of formula I" are used interchangeably and refer to a compound having the structure of formula I, or an optical isomer or racemate thereof, or a pharmaceutically acceptable salt thereof. It is to be understood that the term also includes mixtures of the above components;
in particular, the compound of formula I is as described above in the first aspect of the invention.
Typically, the compounds of formula I according to the present invention are selected from the following table a:
TABLE A
Typically, the compounds of formula I according to the invention are selected from the compounds prepared according to the examples of the invention.
The compounds of formula I as described in this aspect can be prepared by organic synthesis methods well known in the art.
The term "pharmaceutically acceptable salt" refers to a salt of a compound of the present invention with an acid or base that is suitable for use as a pharmaceutical. One preferred class of salts is that formed with acids of the compounds of the present invention, and suitable acids for forming salts include (but are not limited to): inorganic acids such as hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, nitric acid, phosphoric acid, etc., and organic acids such as formic acid, acetic acid, trifluoroacetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, picric acid, methanesulfonic acid, benzenesulfonic acid, etc. One preferred class of salts are metal salts of the compounds of the present invention formed with bases, suitable bases for forming the salts include (but are not limited to): inorganic bases such as sodium hydroxide, potassium hydroxide, sodium carbonate, sodium hydrogencarbonate and sodium phosphate, and organic bases such as ammonia, triethylamine and diethylamine.
Compositions or formulations
The composition of the present invention is preferably a pharmaceutical composition. The compositions of the present invention may include a pharmaceutically acceptable carrier.
In a preferred embodiment of the present invention, the pharmaceutical composition of the present invention comprises a compound of formula I of the present invention, or an optical isomer or racemate thereof, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
In another preferred embodiment of the present invention, the pharmaceutical composition further comprises an antibiotic.
Typically, the antibiotic includes a quinolone antibiotic, such as a fluoroquinolone antibiotic.
Typically, the quinolone antibiotic comprises norfloxacin.
As used herein, "pharmaceutically acceptable carrier" refers to one or more compatible solid, semi-solid, liquid, or gel fillers that are suitable for human or animal use and must be of sufficient purity and sufficiently low toxicity. By "compatible" is meant that the components of the pharmaceutical composition and the active ingredient of the drug are blended with each other and not significantly detract from the efficacy of the drug.
It is to be understood that, in the present invention, the pharmaceutically acceptable carrier is not particularly limited, and may be prepared from materials commonly used in the art, or by conventional methods, or may be commercially available. Examples of pharmaceutically acceptable carrier moieties are cellulose and its derivatives (e.g., methylcellulose, ethylcellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, etc.), gelatin, talc, solid lubricants (e.g., stearic acid, magnesium stearate), calcium sulfate, vegetable oils (e.g., soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (e.g., propylene glycol, glycerin, mannitol, sorbitol, etc.), emulsifiers (e.g., tween), wetting agents (e.g., sodium lauryl sulfate), buffers, chelating agents, thickeners, pH adjusters, transdermal enhancers, colorants, flavors, stabilizers, antioxidants, preservatives, bacteriostats, pyrogen-free water, etc.
The invention also provides an active ingredient combination, which comprises the compound shown in the formula I, or an optical isomer or racemate thereof, or pharmaceutically acceptable salt thereof; and antibiotics. Preferably, the antibiotic comprises a quinolone antibiotic, such as a fluoroquinolone antibiotic. Typically, the quinolone antibiotic comprises norfloxacin.
In the present invention, the dosage form of the composition includes, but is not limited to, oral preparation, injection preparation, and external preparation. Typically, the dosage form of the composition includes, but is not limited to, tablets, injections, infusions, pastes, gels, solutions, microspheres, films.
The pharmaceutical formulation should be compatible with the mode of administration, preferably oral, injection (e.g., intratumoral injection), and is administered by administering a therapeutically effective amount of the drug to a subject in need thereof (e.g., a human or non-human mammal). The term "therapeutically effective amount," as used herein, refers to an amount that produces a function or activity in and is acceptable to humans and/or animals. It will be understood by those skilled in the art that the "therapeutically effective amount" may vary with the form of the pharmaceutical composition, the route of administration, the excipients used, the severity of the disease, and the combination with other drugs.
A safe and effective daily dosage of the active ingredient is usually at least about 0.1mg, and in most cases no more than about 2500 mg. Preferably, the dose is 1mg to 500 mg; of course, the particular dosage will depend upon such factors as the route of administration, the health of the patient, and the like, and is within the skill of the skilled practitioner.
Use of
The invention provides application of a compound shown in a formula I, or an optical isomer or racemate thereof, or pharmaceutically acceptable salt thereof in preparing a medicament for enhancing the antibacterial curative effect of antibiotics.
The invention also provides the application of the pharmaceutical composition or the active ingredient combination in the preparation of antibacterial drugs.
The present invention also provides a method for enhancing the antibacterial efficacy of an antibiotic, said method comprising the steps of: administering a compound of formula I, or an optical isomer or racemate thereof, or a pharmaceutically acceptable salt thereof, according to the present invention to a subject in need thereof.
The present invention also provides a method for antimicrobial activity, said method comprising the steps of: the active ingredient combinations according to the invention are administered to a subject in need thereof.
In a preferred embodiment of the invention, the antibiotic comprises a quinolone antibiotic, preferably a fluoroquinolone antibiotic.
Typically, the quinolone antibiotic comprises norfloxacin.
In a preferred embodiment of the invention, the antimicrobial comprises antibacterial. Preferably, the bacteria comprise drug-resistant bacteria.
Typically, the bacteria include gram-positive bacteria.
Typically, the gram-positive bacteria include staphylococci.
Typically, the staphylococcus includes a staphylococcus aureus strain.
Typically, the staphylococcus aureus strain comprises a multidrug resistant staphylococcus aureus strain SA-1199B containing a NorA efflux pump resistance gene.
The main technical effects obtained by the invention comprise:
1. the invention develops a compound with a novel structure, which can remarkably enhance the antibacterial effect of antibiotics, thereby reducing the dosage of the antibiotics and reducing the generation of bacterial drug resistance.
2. The compound has excellent injection and oral pharmacokinetic characteristics, has excellent absolute bioavailability when being taken orally, is suitable for being taken orally, has high safety and good pharmacy, and is easy for industrial production.
The invention will be further illustrated with reference to the following specific examples. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention.
EXAMPLE 1 preparation of Compounds I-A
Step (1): synthesis of Compound B2
In an ice-water bath, to a solution of Compound B1(2.0g, 11.4mmol) in tetrahydrofuran (30mL) was added isoindoline-1, 3-bisKetone (2.52g, 17.1mmol), PPh3(4.49g, 17.1mmol) and DIAD (3.46g, 17.1mmol), and the reaction mixture was stirred at room temperature overnight. The reaction mixture is then washed with H2O (30mL) was diluted and extracted with ethyl acetate (30 mL. times.2). The combined organic layers were washed with brine (50mL), Na2SO4Dried, filtered and concentrated. The residue was purified by reverse phase silica gel chromatography (acetonitrile/H)2O5% -95%, 254nm, 30min) to give compound B2(2.68g) as a white solid.
MS calculated: 304; MS found: 305[ M + H]+。
Step (2): synthesis of Compound B3
To a solution of compound B2(2.68g, 8.81mmol) in ethanol (20mL) was added HCl/ethanol (20mL) and the reaction mixture was stirred at 50 ℃ overnight. The reaction mixture was then filtered and washed with ethanol (20 mL). The residue was concentrated to give compound B3(1.71g) as a white solid.
MS calculated: 204; MS found: 205[ M + H ]]+。
And (3): synthesis of Compound 2
A solution of compound 1(10g, 44.46mmol) in NaOH (1.95g, 48.90mmol) (50mL) was stirred at 50 ℃ for 1 h. Then adding NaNO into the reaction system at 0 DEG C2(3.05g, 44.46mmol) and H2SO4(8.66g, 88.92mmol) (100mL) was added after 1h at 0 deg.C a solution of SnCl2(23.93g, 106.7mmol) in HCl (40mL) and the reaction mixture was stirred at room temperature overnight. The reaction mixture was then filtered and concentrated to give compound 2(37.8g) as a yellow solid.
MS calculated: 241, a first electrode and a second electrode; MS found: 242[ M + H ]]+。
And (4): synthesis of Compound 3
To a solution of Compound 2(32g, 0.13mol) in MeOH (200mL) at 0 deg.C was added H2SO4(20mL), the mixture was stirred at 90 ℃ overnight. The reaction mixture was then concentrated. The residue was diluted with water (50mL) and extracted with ethyl acetate (50 mL. times.2). The combined organic layers were washed with brine (50 mL. times.2), Na2SO4Dried, filtered and concentrated. The residue was purified by silica gel chromatography (petroleum ether/ethyl acetate 3/1-EA) to give compound 3(22.8g) as a yellow solid.
MS calculated: 255; MS found: 256[ M + H ]]+。
And (5): synthesis of Compound 4
SEM: (trimethylsilyl) ethoxymethyl group
To a solution of compound 3(10g, 39.2mmol) in DMF (100mL) at 0 deg.C was added NaH (2.35g, 58.8mmol) and stirred at 0 deg.C for 1 h. 2- (trimethylsilyl) ethoxymethyl chloride (SEMCl) (7.84g, 47.0mmol) was added and the resulting mixture was stirred at room temperature for 3 h. The reaction was then diluted with water (50mL) and extracted with ethyl acetate (50 mL. times.2). The combined organic layers were washed with brine (50 mL. times.2), Na2SO4Dried, filtered and concentrated. The residue was purified by silica gel chromatography (petroleum ether/ethyl acetate 20/1-10/1) to give compound 4(11.07g) as a yellow solid.
MS calculated: 384; MS found: 385[ M + H ]]+。
And (6): synthesis of Compound 5
To compound 4(4.84mg, 12.6mmol) was added 1, 4-bisTo a solution of Pin2B2(4.80g, 18.9mmol) and K in dioxane (50mL) was added2CO3(5.22g, 37.8mmol) and Pd (PPh3)4(1.46g, 0.126mmol), and the mixture was heated to 100 ℃ under N2 overnight. The reaction was then cooled to room temperature and quenched with H2O (50mL) was diluted and extracted with ethyl acetate (50 mL. times.2). The combined organic layers were washed with brine (100 mL. times.2), Na2SO4Dried, filtered and concentrated. The residue was purified by silica gel chromatography (petroleum ether/ethyl acetate 15/1-10/1) to give compound 5(4.0g) as a white solid.
MS calculated: 432; MS found: 433[ M + H ]]+。
And (7): synthesis of Compound 6
To a solution of compound 5(2.0g, 4.63mmol) in THF (20mL) was added NaOH to adjust pH to 9. After 10min, H was added2O2(2.62g, 23.14mmol) and the mixture was stirred at room temperature for 2 h. The reaction mixture is then washed with H2O (30mL) was diluted and extracted with ethyl acetate (30 mL. times.2). The combined organic layers were washed with brine (50mL), Na2SO4Dried, filtered and concentrated. The residue was purified by silica gel chromatography (petroleum ether/ethyl acetate 5/1) to give compound 6(1.4g) as a yellow solid.
MS calculated: 322, respectively; MS found: 323[ M + H]+。
And (8): synthesis of Compound 7
To a solution of compound 6(1.0g, 3.1mmol) in DMF (30mL) was added methyl 3-fluoropicolinate (578mg, 3.7mmol) and Cs2CO3(2.02g, 6.2mmol) and the mixture was stirred at 120 ℃ overnight. The reaction mixture is then washed with H2O (30mL) was diluted and extracted with ethyl acetate (30 mL. times.2). The combined organic layers were washed with brine (50mL), Na2SO4Dried, filtered and concentrated. The residue was purified by reverse phase silica gel chromatography (acetonitrile/H)2O ═ 5% to 95%, 254nm, 30 minutes), compound 7(0.7g) was obtained as a yellow solid.
MS calculated: 429; MS found: 430[ M + H ]]+。
And (9): synthesis of Compound 8
To a solution of compound 7(300mg, 0.7mmol) in DMF (15mL) was added compound B3(143mg, 0.7mmol), DIEA (271mg, 2.1mmol) and HATU (400mg, 1.05 mmol). The reaction was diluted with water (20mL) and extracted with ethyl acetate (30 mL. times.2). The combined organic layers were washed with brine (50mL) and Na2SO4Dried, filtered and concentrated. The residue was purified by reverse phase silica gel chromatography (acetonitrile/H)2O ═ 5% to 95%, 254nm, 30min) to give compound 8(43mg) as a yellow solid.
MS calculated: 615; MS found: 616[ M + H [ ]]+。
Step (10): synthesis of Compound 9
To a solution of compound 8(73mg, 0.12mmol) in EtOH (20mL) was added NH2NH2·H2O (21mg, 0.36mmol), and the mixture was stirred at 65 ℃ for 5 h. The reaction mixture was concentrated and the residue was purified by reverse phase silica gel chromatography (acetonitrile/H)2O ═ 5% to 95%, 254nm, 30min), compound 9(23mg) was obtained as a yellow solid.
MS calculated: 485; MS found: 486[ M + H]+。
Step (11): synthesis of Compound 10
To a solution of compound 9(23mg, 0.05mmol) in DMF (15mL) were added TEA (1 drop) and HATU (36mg, 0.10mmol) and the mixture was stirred at room temperature for 1 h. The reaction was then diluted with water (10mL) and extracted with ethyl acetate (20 mL. times.2). The combined organic layers were washed with brine (50mL) and Na2SO4Dried, filtered and concentrated. The residue was purified by preparative HPLC to give compound 10(6mg) as a white solid.
MS calculated: 467; MS found: 468[ M + H]+。
Step (12): synthesis of Compound I-A
To a solution of compound 10(50mg, 0.1mmol) in DCM (10mL) was added bf3.et2o (0.5mL) at 0 ℃ and the mixture was stirred at rt overnight. The reaction mixture was adjusted to pH 8 with 4M NaOH and extracted with ethyl acetate (20mL × 2). Concentration gave a residue which was purified by HPLC to give compound I-A (5mg) as a white solid.
MS calculated: 337; MS found: 338[ M + H]+。
Compound I-A1H NMR(400MHz,DMSO-d6)δ:13.08(t,J=20.2Hz,1H),8.69-8.49(m,1H),8.18(d,J=4.0Hz,1H),7.84-7.74(m,1H),7.39-7.20(m,2H),7.16-7.08(m,1H),6.85-6.80(m,1H),6.63-6.54(m,1H),4.46(brs,1H),3.77-3.65(m,1H),3.13-3.08(m,1H),1.22(d,J=6.8Hz,3H)。
EXAMPLE 2 preparation of Compounds I-B
Step (1): synthesis of Compound 2
SEM: (trimethylsilyl) ethoxymethyl.
To a solution of Compound 1(1.0g, 3.1mmol) in DMF (10mL) was added Compound 1-2(0.50g, 4.7mmol) and K2CO3(1.28g, 9.3 mmol). The reaction mixture was stirred at 120 ℃ for 1 h. Subjecting the reaction mixture to hydrogenation with H2O (30mL) was diluted and extracted with ethyl acetate (30 mL. times.2). The combined organic layers were washed with brine (50mL) and Na2SO4Dried, filtered and concentrated. The residue was purified by silica gel chromatography (petroleum ether/ethyl acetate 10/1) to give compound 2(0.6g) as a yellow oil.
MS (mass spectrometry) calculated: 426, respectively; MS found: 427[ M + H]+。
Step (2): synthesis of Compound 3
To a solution of compound 2(0.55g, 1.3mmol) in acetone (10mL) was added jones reagent (2mL), the reaction mixture was stirred at room temperature for 1h, then the reaction mixture was diluted with water (20mL) and extracted with ethyl acetate (30mL × 2). The combined organic layers were washed with brine (50mL) and Na2SO4Drying, filtration and concentration gave compound 3(0.6g) as a yellow oil.
MS calculated: 442; MS found: 443[ M + H ]]+。
And (3): synthesis of Compound 4
To a solution of compound 3(500mg, 1.1mmol) in DMF (10mL) were added HATU (644.8mg, 1.7mmol), triethylamine (342.8mg, 3.4mmol) and compound 3-1(391.5mg, 1.7mmol) and the reaction mixture was stirred at room temperature for 4 h. The reaction was then diluted with water (20mL) and extracted with ethyl acetate (30 mL. times.2). The combined organic layers were washed with brine (50mL) and Na2SO4Dried, filtered and concentrated. Passing the residue throughPurification by silica gel chromatography (petroleum ether/ethyl acetate 4/1) gave compound 4(0.6g) as a yellow oil.
MS calculated: 618; MS found: 619[ M + H]+。
And (4): synthesis of Compound 5
To compound 4(600mg, 1.0mmol) in MeOH (10mL) and H2To a solution of O (1mL) was added LiOH (203.9mg, 4.9mmol) and the reaction mixture was stirred at 50 ℃ for 2 h. The reaction mixture was then adjusted to pH 4-5 with 5% HCl and extracted with ethyl acetate (50 mL. times.2). The combined organic layers were washed with brine (50mL) and Na2SO4Drying, filtration and concentration gave compound 5(0.55g) as a yellow solid.
MS calculated: 604; MS found: 605[ M + H]+。
And (5): synthesis of Compound 6
To a solution of compound 5(550mg, 0.91mmol) in MeOH (10mL) was added Pd/C (100mg) and the reaction mixture was taken up in H2Stirred under the atmosphere at 50 ℃ for 2 h. The reaction mixture was filtered and concentrated to give compound 6(400mg) as a colorless solid.
MS (mass spectrometry) calculated: 470, respectively; MS found: 471[ M + H]+。
And (6): synthesis of Compound 7
To a solution of compound 6(300mg, 0.64mmol) in DMF (150mL) were added HATU (485.1mg, 1.3mmol) and triethylamine (193.4mg, 1.9mmol), and the reaction mixture was stirred at room temperature for 1 h. The reaction was then diluted with water (300mL) and acetic acidExtraction with ethyl ester (300 mL. times.2). The combined organic layers were washed with brine (200mL) and Na2SO4Dried, filtered and concentrated to 10 mL. The suspension was then filtered to give compound 7 as a white solid (130 mg).
MS (mass spectrometry) calculated: 452; MS found: 905[2M + H ] +.
And (7): synthesis of Compounds I-B
To a solution of compound 7(50mg, 0.11mmol) in DCM (2mL) at 0 deg.C was added BF3.Et2O (2 mL). The reaction mixture was stirred at room temperature for 1h, then adjusted to pH 10 with 4M NaOH and extracted with ethyl acetate (20mL × 2). Concentration gave a residue which was purified by HPLC to give compound I-B as a white solid (3 mg).
MS calculated: 322, respectively; MS found: 323[ M + H]+
Compounds I-B1H NMR(400MHz,DMSO-d6)δ:13.41(s,1H),8.44(s,2H),7.93(d,J=1.6Hz,1H),7.87-7.84(m,1H),7.35(d,J=9.2Hz,1H),7.27-7.23(m,1H),7.08-7.05(m,1H),6.94-6.91(m,1H),6.49(d,J=8Hz,1H),3.59(d,J=10.8Hz,4H),1.22(d,J=6.8Hz,3H)。
EXAMPLE 3 preparation of Compounds I-C
Step (1): synthesis of Compound 2
SEM: (trimethylsilyl) ethoxymethyl.
To a solution of Compound 1(0.5g, 1.6mmol) in DMF (10mL) was added Compound 1-2(0.29g, 2.3mmol) and K2CO3(0.66g, 4.8mmol) and reaction mixture at 1Stirring at 20 ℃ for 1 h. The reaction mixture is then washed with H2O (30mL) was diluted and extracted with ethyl acetate (30 mL. times.2). The combined organic layers were washed with brine (50mL), Na2SO4Dried, filtered and concentrated, and the residue was purified by silica gel chromatography (petroleum ether/ethyl acetate 10/1) to give compound 2(0.45g) as a yellow solid.
MS calculated: 443; MS found: 444[ M + H ]]+。
Step (2): synthesis of Compound 3
To a solution of compound 2(0.45g, 1.0mmol) in EtOH (10mL) was added Fe (568.8mg, 10.1mmol) and NH4Cl (543.5mg, 10.1mmol) and the reaction mixture was stirred at 80 ℃ for 1 h. The reaction mixture was then filtered over H2O (20mL) was diluted and extracted with ethyl acetate (50 mL. times.2). The combined organic layers were washed with brine (50mL), Na2SO4Drying, filtration and concentration gave compound 3(0.4g) as a yellow solid.
MS calculated: 413; MS found: 414[ M + H]+。
And (3): synthesis of Compound 4
To a solution of compound 3(400mg, 0.97mmol) in DMF (10mL) were added HATU (552.1mg, 1.45mmol), triethylamine (293.5mg, 2.9mmol) and compound 3-1(325.4mg, 1.45mmol) and the reaction mixture was stirred at room temperature for 4 h. The reaction was then diluted with water (50mL) and extracted with ethyl acetate (50 mL. times.2). The combined organic layers were washed with brine (50mL), Na2SO4Dried, filtered and concentrated. The residue was purified by silica gel chromatography (petroleum ether/ethyl acetate 4/1) to give compound 4(0.5g) as a white solid.
MS calculated: 618; MS found: 619[M+H]+。
And (4): synthesis of Compound 5
To compound 4(500mg, 0.81mmol) in MeOH (10mL) and H2To a solution of O (1mL) was added LiOH (169.9mg, 4.0mmol) and the reaction mixture was stirred at 50 ℃ for 2 h. The reaction mixture was then adjusted to pH 4-5 with 5% HCl and extracted with ethyl acetate (50 mL. times.2). The combined organic layers were washed with brine (50mL) and Na2SO4Drying, filtration and concentration gave compound 5(0.45g) as a yellow solid.
MS calculated: 604; MS found: 605[ M + H]+。
And (5): synthesis of Compound 6
To a solution of compound 5(450mg, 0.75mmol) in MeOH (10mL) was added Pd/C (100mg) and the reaction mixture was taken up in H2Stirred under the atmosphere at 50 ℃ for 2 h. The reaction mixture was filtered and concentrated to give compound 6(300mg) as a white solid.
MS calculated: 470, respectively; MS found: 471[ M + H]+。
And (6): synthesis of Compound 7
To a solution of compound 6(350mg, 0.74mmol) in DMF (150mL) were added HATU (556.0mg, 1.5mmol) and triethylamine (225.6mg, 2.2mmol) and the reaction mixture was stirred at room temperature for 1 h. The reaction was then diluted with water (300mL) and extracted with ethyl acetate (300 mL. times.2). The combined organic layers were washed with brine (200 mL. times.2), Na2SO4Dried, filtered and concentrated to 10 mL. The suspension is then filtered to give a white solidCompound 7(100 mg).
MS calculated: 452; MS found: 905[2M + H ] +.
And (7): synthesis of Compounds I-C
To a solution of compound 7(70mg, 0.15mmol) in DCM (2mL) was added bf3.et2o (2mL) at 0 ℃ and the reaction mixture was stirred at rt for 1 h. The reaction solution was adjusted to pH 10 with 4M NaOH, and extracted with ethyl acetate (20mL × 2). Concentration gave a residue which was purified by HPLC to give compounds I-C as white solids (9 mg).
MS calculated: 322, respectively; (ii) a MS found: 323[ M +1]
Compounds I-C:1H NMR(400MHz,DMSO-d6)δ:13.30(s,1H),9.20(s,1H),8.27-8.24(t,J=5.4Hz,1H),7.97(d,J=3.4Hz,1H),7.40(d,J=0.8Hz,1H),7.26(d,J=4.4Hz,1H),7.07-6.98(m,2H),6.75-6.69(m,2H),3.53-3.48(t,J=9Hz,2H),2.69-2.67(t,J=4.6Hz,2H)。
EXAMPLE 4 preparation of Compounds I-D
Step (1): synthesis of Compound I-D-4
To a solution of compound I-D-3(1g, 3.1mmol) in DMF (15mL) was added 3-fluoro-2-nitropyridine (660mg, 4.65mmol) and K2CO3(1.3g, 9.3mmol) of the mixture in N2And 108 ℃ for 4 h. The reaction mixture was then cooled to room temperature with H2O (20mL) was diluted and extracted with ethyl acetate (30 mL. times.2). The combined organic layers were washed with brine (50mL), Na2SO4Dried, filtered and concentrated. The residue was purified by silica gel chromatography (ethyl acetate)Ester/petroleum ether ═ 10% to 30%) to give compound I-D-4(1g) as a yellow solid.
MS calculated: 444; MS found: 445[ M + H ]]+。
Step (2): synthesis of Compound I-D-5
To a solution of compound I-D-4(100mg, 0.23mmol) in EtOH (10mL) and water (1mL) was added Fe (126mg, 2.3mmol) and NH4Cl (120mg, 2.3mmol), and the mixture was stirred at 85 ℃ for 2 h. The reaction mixture was cooled to room temperature and washed with H2O (20mL) was diluted and extracted with ethyl acetate (20 mL. times.2). The combined organic layers were washed with brine (50 mL. times.2), Na2SO4Dried, filtered and concentrated. The residue was purified by silica gel chromatography (petroleum ether/ethyl acetate 1/1) to give compound I-D-5(90mg) as a yellow solid.
MS calculated: 414; MS found: 415[ M + H]+。
And (3): synthesis of Compound I-D-6
To a solution of compound I-D-5(450mg, 1.09mmol) in 1, 4-dioxane (15mL) was added 3- (((((benzyloxy) carbonyl) amino) butanoic acid (1g, 4.36mmol), DIEA (1.68g, 13.08mmol) and HATU (1.9g, 4.91mmol)2And reacted at 85 ℃ overnight. The reaction mixture was then cooled to room temperature with H2O (20mL) was diluted and extracted with ethyl acetate (30 mL. times.2). The combined organic layers were washed with brine (50mL), Na2SO4Dried, filtered and concentrated. The residue was purified by silica gel chromatography (DCM/MeOH ═ 100/1) to give compound I-D-6(600mg) as a yellow solid.
MS calculated: 633; MS found: 634[ M + H ]]+。
And (4): synthesis of Compound I-D-7
To a solution of compound I-D-6(50mg, 0.079mmol) in MeOH (10mL) and water (2mL) was added LiOH (6.6mg, 0.158mmol) and the mixture was stirred at room temperature for 5 h. The reaction mixture was then adjusted to pH 4 with 5% HCl and extracted with ethyl acetate (30mL × 2). The combined organic layers were washed with brine (100mL), Na2SO4Drying, filtration and concentration gave compound I-D-7 (30mg) as a yellow solid.
MS calculated: 619; MS found: 620[ M + H ]]+。
And (5): synthesis of Compound I-D-8
To a solution of compound I-D-7(160mg, 0.26mmol) in MeOH (5mL) was added Pd (OH)2(50mg), and the mixture was stirred under hydrogen at room temperature overnight. The reaction mixture was then filtered and concentrated to give compound I-D-8(100mg) as a yellow solid.
MS calculated: 485; MS found: 486[ M + H]+。
And (6): synthesis of Compound I-D-9
To a solution of compound I-D-8(140mg, 0.29mmol) in DMF (140mL) was added triethylamine (59mg, 0.58mmol) and HATU (220mg, 0.58 mmol). The mixture was stirred at room temperature for 2 h. The reaction mixture was then diluted with water (200mL) and extracted with ethyl acetate (300 mL. times.2). The combined organic layers were washed with brine (50mL), Na2SO4Dried, filtered and concentrated. The residue was purified by preparative HPLC to give Compound I-D-9 as a white solid (6mg, 4% yield).
MS calculated: 467; MS found: 468[ M + H]+。
And (7): synthesis of Compounds I-D
To a solution of compound I-D-9(6mg, 0.013mmol) in DCM (30mL) at 0 ℃ was added bf3.et2o (8 drops) and the mixture was stirred at rt for 3 h. The reaction mixture was then concentrated and adjusted to pH 10 with 4M NaOH and extracted with ethyl acetate (10mLx2) and concentrated to give compound I-D as a white solid (1.5 mg).
MS calculated: 337; MS found: 338[ M + H]+。
Compounds I to D1H NMR(400MHz,DMSO-d6)δ:9.92(s,1H),8.11(d,J=4.4Hz,1H),7.98(d,J=8.0Hz,1H),7.30-7.28(m,2H),7.17-7.10(m,2H),6.87(d,J=8.8Hz,1H),4.31(s,1H),2.84-2.78(m,1H),1.66(s,2H),1.23(d,J=6.0Hz,3H)
EXAMPLE 5 preparation of Compounds I-E
Step (1): synthesis of Compound I-E-2
To a solution of compound I-E-1(1g, 6.5mmol) in tetrahydrofuran/methanol (5mL/5mL) was added methylamine hydrochloride (1.3g, 20mmol) and triethylamine (3.2g, 32mmol), the mixture was stirred at room temperature for 6h, then NaBH3CN (1.3g, 21mmol) was added to the reaction mixture, and the mixture was stirred at room temperature overnight. The reaction was diluted with water (10mL) and extracted with dichloromethane (30 mL. times.2) and concentrated to give compound I-E-2 as a yellow oil, which was used without any purification.
MS (mass spectrometry) found: 171[ M + H]+
Step (2): synthesis of Compound I-E-3
To a solution of compound I-E-2(1.1g, 6.5mmol) in ethanol (20mL) was added compound S2(1.4g, 6.2mmol) and DIEA (2.3g, 18mmol), and the mixture was stirred at 80 ℃ for 12 h. The reaction solution was then diluted with water (10mL) and extracted with ethyl acetate (10 mL. times.2). The combined organic layers were washed with brine (20mL), Na2SO4Dried, filtered and concentrated, and the residue was purified by silica gel chromatography (petroleum ether/ethyl acetate 2/1) to give compound I-E-3(2g) as a white solid.
MS (mass spectrometry) found: 360[ M + H ]]+。
And (3): synthesis of Compound I-E-4
To a solution of compound I-E-3(2g, 5.6mmol) in acetonitrile (50mL) at 0 deg.C was added AlCl3(7.5g, 56mmol) and NaI (8.4g, 56mmol), and the mixture was stirred at room temperature for 12 h. The reaction solution was diluted with water (10mL) and extracted with ethyl acetate (10 mL. times.2). The combined organic layers were washed with brine (20mL), Na2SO4Dried, filtered and concentrated, and the residue was purified by silica gel chromatography (dichloromethane/ethanol ═ 10/1) to give compound I-E-4(1.6g) as a yellow solid.
MS (mass spectrometry) found: 346[ M + H ]]+。
And (4): synthesis of Compound I-E-5
To a solution of compound I-E-4(100mg, 0.3mmol) in dichloromethane (10mL) at 0 deg.C was added Tf2O (245mg, 0.9mmol) and DIEA (224mg, 1.7mmol), and the mixture was stirred at room temperature for 12 h. Using the reaction solutionWater (10mL) was diluted and extracted with dichloromethane (10 mL. times.2). The combined organic layers were washed with brine (20mL), Na2SO4Dried, filtered and concentrated, and the residue was purified by silica gel chromatography (petroleum ether/ethyl acetate 3/1) to give compound I-E-5(100mg) as a yellow solid.
MS (mass spectrometry) found: 478[ M + H]+。
And (5): synthesis of Compound I-E-6
To a solution of compound I-E-5(500g, 1.1mmol) in DMF (10mL) was added (R) -tert-butylbut-3-yn-2-ylcarbamate (360g, 2.1mmol), Pd (PPh3))2Cl2(250mg, 0.4mmol), CuI (250mg, 1.3mmol), and Et3N (270mg, 2.7mmol), and the mixture was stirred at 70 ℃ for 12 h. The reaction mixture was cooled to room temperature and washed with H2O (30mL) was diluted and extracted with ethyl acetate (50 mL. times.2). The combined organic layers were washed with brine (20mL), Na2SO4Dried, filtered and concentrated. The residue was purified by silica gel chromatography (petroleum ether/ethyl acetate 1/1) to give compound I-E-6(500mg) as a yellow solid.
MS (mass spectrometry) found: 497[ M + H]+。
And (6): synthesis of Compound I-E-7
To a solution of compound I-E-6(220mg, 0.4mmol) in ethanol (6mL) was added PtO2(86mg, 0.38mmol) and the mixture was dissolved in H2(1atm) and stirring at room temperature for 12 h. The reaction was then filtered and concentrated. The residue was purified by silica gel chromatography (H)2(1atm) ═ 1/1) to give compound I-E-7(200mg) as a yellow solid.
MS (mass spectrometry) found: 501[ M + H [ ]]+
And (7): synthesis of Compound I-E-8
Trifluoroacetic acid (5mL) was added to a solution of compound I-E-7(200mg, 0.4mmol) in DCM (5mL), and the reaction mixture was stirred at room temperature for 1h and then concentrated to give compound I-E-8(2.5g) as a yellow oil.
MS (mass spectrometry) found: 401[ M + H]+
And (8): synthesis of Compound I-E-9
To a solution of compound I-E-8(200mg, 0.5mmol) in ethanol (15mL) and water (3mL) was added NaOH (20mg, 5mmol) and the mixture was stirred at 70 ℃ for 6 h. The reaction mixture was then adjusted to pH 7 with 5% HCl and extracted with ethyl acetate (50 mL. times.3). The combined organic layers were washed with brine (20mL), Na2SO4Drying, filtration and concentration gave compound I-E-9(180mg) as a yellow solid.
MS (mass spectrometry) found: 373[ M + H ]]+
And (9): synthesis of Compounds I-E
To a solution of compound I-E-9(200mg, 0.5mmol) in DMF (80mL) were added HOBT (218mg, 1.6mmol), EDCI (310mg, 1.6mmol) and Et3N (310mg, 1.6mmol), and the mixture was stirred at room temperature for 12 h. The reaction solution was diluted with water (50mL) and extracted with dichloromethane (30 mL. times.2). The combined organic layers were washed with brine (50mL), Na2SO4Dried, filtered and concentrated. The residue was purified by silica gel chromatography (dichloromethane/methanol-15/1) to give compound I-E (20mg) as a white solid.
MS calculated: 354; MS (mass spectrometry) found: 355[ M + H ] +.
Compounds I to E1H NMR(400MHz,DMSO-d6)δ:8.78(d,J=8Hz,1H),8.40(s,1H),8.34(d,J=8Hz,1H),8.04(s,1H),7.49(d,J=9.6Hz,1H),6.79(d,J=7.6Hz,1H),5.46(d,J=15.6Hz,1H),4.36(d,J=15.6Hz,1H),4.15(br s,1H),3.60(s,3H),3.39-3.33(m,1H),2.79-2.64(m,2H),2.09-2.03(m,1H),1.24(d,J=5.6Hz,3H)。
Example 6 investigation of the synergistic Effect of Compounds on antibiotics
SA-1199B strain: multidrug resistance staphylococcus aureus strain SA-1199B containing NorA external pump resistance gene.
MTT: thiazole blue, 3- (4, 5-dimethyl-2-thiazolyl) -2, 5-diphenyl-2H-tetrazolium bromide.
Experimental methods
The Minimum Inhibitory Concentration (MIC) is determined by a conventional dilution method and a drug sensitivity method, and the method comprises the following steps:
norfloxacin, the different compounds prepared in inventive examples 1-5, or norfloxacin and the different compounds prepared in inventive examples 1-5 were mixed according to 1: 1 by weight ratio, the resulting composition was dissolved in DMSO and then prepared into a mother liquor with a broth. In a 96-well plate, different drugs were diluted to different concentrations in broth using a serial two-fold micro-well dilution method, and then 100. mu.l of 10 was added to each well6CFU/mL SA-1199B suspension, 96-well plates in 37 ℃ incubator for 18h, each well adding 20 u L5 mg/mL MTT for detecting bacterial growth, MTT from yellow to blue indicating bacterial growth, each concentration set 3 multiple wells, repeat 3 times. Observing the result; the Minimum Inhibitory Concentration (MIC) of different drugs to SA1199B strain is shown in Table 1, where the minimum concentration of the drug required for the complete absence of growth is the MIC value of the drug to this strain:
TABLE 1 Minimum Inhibitory Concentrations (MIC) of different drugs against SA1199B strain are shown in Table 1
As can be seen from Table 1, the MIC of the compound of the invention applied alone is more than 128 mug/ml, therefore, the compound of the invention applied alone can not generate inhibition effect on the SA-1199B strain, however, when the compound of the invention is applied in combination with norfloxacin, the antibacterial effect of norfloxacin on the SA-1199B strain can be obviously enhanced, thereby showing that the compound of the invention has excellent antibacterial synergistic effect.
Example 7 in vivo examination of the antibacterial efficacy of Compounds I-E prepared in example 5 of the invention
1. Preparing the medicine:
blank solvent: physiological saline containing 0.5 wt% sodium carboxymethylcellulose.
Norfloxacin solution: adding norfloxacin into a blank solvent, mixing and dispersing to obtain the norfloxacin.
Solutions of compounds I-E: adding the compound I-E into a blank solvent, mixing and dispersing to obtain the compound I-E.
Preparing SA-1199B bacterial liquid: taking a multi-drug resistant staphylococcus aureus strain SA-1199B liquid containing a NorA external pump drug resistant gene, streaking and inoculating the multi-drug resistant staphylococcus aureus strain SA-1199B liquid on an MH plate, culturing for 24 hours, inoculating the multi-drug resistant staphylococcus aureus strain in an MH liquid culture medium, culturing at 37 ℃, centrifuging, removing supernatant, washing with PBS buffer solution, and uniformly mixing with the PBS buffer solution.
2. Experimental methods
Male ICR mice weighing 18-22g were randomly divided into a blank control group, a SA-1199B strain group, a norfloxacin group, an I-E group, and an I-E + norfloxacin group, with 8 mice per group. The mice in the blank control group were not treated, and the mice in the SA-1199B strain group, norfloxacin group, I-E group, and I-E + norfloxacin group were injected with 0.2mL of SA-1199B bacterial solution (10mL) into tail vein respectively6CFU/mL). After l h bacterial infection, mice in the blank control group, the SA-1199B strain group, the norfloxacin group, the I-E group and the I-E + norfloxacin group were respectively administered with the following drugs by intragastric administration:
blank control group: blank vehicle.
SA-1199B Strain group: blank vehicle.
Norfloxacin group: norfloxacin solution, wherein the dosage of norfloxacin is 180mg/kg body weight;
groups I-E: compound I-E solution, compound I-E administration amount is 100mg/kg body weight;
group I-E + norfloxacin: norfloxacin solution and compound I-E solutions were administered at a norfloxacin dose of 180mg/kg body weight and compound I-E doses of 100mg/kg body weight.
After the administration, each group of mice was normally fed and observed for survival at 24 hours, and the survival at 24 hours of each mouse after the administration is shown in table 2.
TABLE 2 survival status of the respective mice at 24h after dosing
As can be seen from Table 2, when the compound I-E and norfloxacin are used in combination, the antibacterial effect of norfloxacin on SA-1199B strains can be remarkably enhanced, so that the compound I-E has excellent antibacterial synergistic effect.
Example 8 examination of the pharmacokinetics of the Compounds I-E of the invention prepared in example 5
Experimental methods
Administration method and sampling time: clean-grade BALB/c mice were randomly divided into two groups, two groups of mice were administered with compounds I-E by intravenous (2mg/kg) injection and oral gavage (10mg/kg), blood was collected at time points of 0.0833, 0.25, 0.5, 1.0, 2, 4, 8, 12 and 24h to extract plasma, LC-MS was used to measure the blood concentration of compounds I-E at different time points, 3 mice per blood collection point were used in parallel, and pharmacokinetic parameters were determined using a non-atrioventricular model, and the pharmacokinetic parameters are shown in Table 3.
Table 3 pharmacokinetic parameters (n ═ 3, Mean)
Note: kel: a rate of end cancellation; t ismax: time corresponding to maximum blood concentration; cmax: the highest blood concentration; AUC0-t: area under curve when medicine is taken for 0-24 h; AUC0-∞: area under the curve of the time of administration at 0-infinity; t is t1/2: a half-life; vss: a steady state apparent distribution volume; v: apparent volume of distribution; cl: the clearance rate; f: absolute bioavailability.
Table 3 shows that the compounds I to E have excellent pharmacokinetic properties in injection and oral administration, and the absolute bioavailability (F) in oral administration is as high as 77.5%, thereby indicating that the compounds I to E can achieve therapeutic effects in injection administration by oral administration, and therefore, the compounds I to E are suitable for oral administration, which has excellent safety and pharmaceutical efficacy, strong patient compliance, and low cost of oral preparations, and is easy for industrial production, compared with intravenous administration.
The above description is only a preferred embodiment of the present application and is not intended to limit the present application, and various modifications and changes may be made by those skilled in the art. Any modification, equivalent replacement, improvement and the like made within the spirit and principle of the present application shall be included in the protection scope of the present application.
Claims (10)
1. A compound of formula I, or an optical isomer or racemate thereof, or a pharmaceutically acceptable salt thereof;
wherein the content of the first and second substances,
ring A is a substituted or unsubstituted C3-C12 cycloalkane ring, a substituted or unsubstituted C6-C16 aromatic ring, a substituted or unsubstituted 3-16 membered heteroaromatic ring, or a substituted or unsubstituted 3-12 membered heterocycloalkyl ring;
ring B is a substituted or unsubstituted C3-C12 cycloalkane ring, a substituted or unsubstituted C6-C16 aromatic ring, a substituted or unsubstituted 3-16 membered heteroaromatic ring, or a substituted or unsubstituted 3-12 membered heterocycloalkyl ring;
Z1is-O-, -S-, substituted or unsubstituted C3-C12 cycloalkylene, substituted or unsubstituted 3-12 membered heterocycloalkylene, or substituted or unsubstituted C1-C6 alkyl-N (R)5)-;
when in useWhen it is a carbon-carbon single bond, Z2is-C (O) -NH-, substituted or unsubstituted C1-C8 alkylene, -O-, -S-; or whenWhen it is a carbon-carbon double bond, Z2is-CH ═ or-R6-CH=;
R1、R2、R3And R4Each independently hydrogen, substituted or unsubstituted C1-C8 alkyl, substituted or unsubstituted C3-C12 cycloalkyl, or substituted or unsubstituted 3-12 membered heterocycloalkyl;
R5is hydrogen, substituted or unsubstituted C1-C6 alkyl, or substituted or unsubstituted C3-C8 cycloalkyl;
R6is a substituted or unsubstituted C1-C6 alkylene group;
wherein any "substitution" means that one or more (preferably 1, 2, 3, 4 or 5) hydrogen atoms on the group are substituted with a substituent selected from the group consisting of: C1-C8 alkyl, C3-C8 cycloalkyl, C1-C8 haloalkyl, C3-C8 halocycloalkyl, halogen, hydroxy, mercapto, amino, C1-C8 alkoxy, C1-C8 alkylthio, C6-C12 aryl, 5-10 membered heteroaryl, 5-10 membered heterocycloalkyl;
the heterocyclic rings of the heteroaryl ring, heterocycloalkyl ring, heteroaryl group and heterocycloalkyl group each independently have 1-4 (preferably 1, 2, 3 or 4) heteroatoms selected from N, O and S.
2. The compound of claim 1, wherein said compound comprises one or more features selected from the group consisting of:
Ring B being substituted or unsubstitutedSubstituted or unsubstitutedOr substituted or unsubstitutedR7 is halogen;
R5is hydrogen, methyl, ethyl, propyl, or butyl;
when in useWhen it is a carbon-carbon single bond, Z2is-C (O) -NH-, methylene, ethylene, propylene, butylene, -O-, or-S-;
R6Is methylene, ethylene, propylene, or butylene; and/or
R1、R2、R3And R4Each independently hydrogen, methyl, ethyl, propyl, or butyl.
5. use of a compound of formula I according to claim 1, or an optical isomer or racemate thereof, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for enhancing the antibacterial effect of an antibiotic.
6. The use of claim 5, wherein said antibiotic comprises norfloxacin; and/or
The said antibiotic includes antibacterial, the said bacterium includes multidrug-resistant Staphylococcus aureus strain SA-1199B containing NorA outer pump resistant gene.
7. A pharmaceutical composition comprising a compound of formula I according to claim 1, or an optical isomer or racemate thereof, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
8. An active ingredient combination comprising a compound of formula I as claimed in claim 1, or an optical isomer or racemate thereof, or a pharmaceutically acceptable salt thereof; and antibiotics.
9. Use of a pharmaceutical composition according to claim 7 or of an active ingredient combination according to claim 8 for the preparation of an antibacterial medicament.
10. The use of claim 9, wherein said anti-bacteria comprises an anti-bacterium comprising multidrug resistant staphylococcus aureus strain SA-1199B containing a NorA efflux pump resistance gene.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110307268.XA CN113072564A (en) | 2021-03-23 | 2021-03-23 | Heteroaromatic ring compound and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110307268.XA CN113072564A (en) | 2021-03-23 | 2021-03-23 | Heteroaromatic ring compound and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113072564A true CN113072564A (en) | 2021-07-06 |
Family
ID=76613320
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110307268.XA Pending CN113072564A (en) | 2021-03-23 | 2021-03-23 | Heteroaromatic ring compound and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113072564A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113332328A (en) * | 2021-06-07 | 2021-09-03 | 山东省千佛山医院 | Medicine for diseases of respiratory and endocrinology departments |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101269060A (en) * | 2007-03-21 | 2008-09-24 | 复旦大学 | Use of compound HSR01-4-9 in preparing multi-drug resistant aureus restrainer |
CN108697708A (en) * | 2015-10-26 | 2018-10-23 | 洛克索肿瘤学股份有限公司 | Point mutation in TRK inhibitor resistant cancers and method related to this |
CN110769820A (en) * | 2017-03-16 | 2020-02-07 | 阿雷生物药品公司 | Macrocyclic compounds as ROS1 kinase inhibitors |
CN110950889A (en) * | 2018-09-27 | 2020-04-03 | 北京赛林泰医药技术有限公司 | Multi-target kinase inhibitor and preparation method and application thereof |
CN111343987A (en) * | 2017-11-10 | 2020-06-26 | 安杰斯制药公司 | Macrocyclic compounds as TRK kinase inhibitors and uses thereof |
-
2021
- 2021-03-23 CN CN202110307268.XA patent/CN113072564A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101269060A (en) * | 2007-03-21 | 2008-09-24 | 复旦大学 | Use of compound HSR01-4-9 in preparing multi-drug resistant aureus restrainer |
CN108697708A (en) * | 2015-10-26 | 2018-10-23 | 洛克索肿瘤学股份有限公司 | Point mutation in TRK inhibitor resistant cancers and method related to this |
CN110769820A (en) * | 2017-03-16 | 2020-02-07 | 阿雷生物药品公司 | Macrocyclic compounds as ROS1 kinase inhibitors |
CN111343987A (en) * | 2017-11-10 | 2020-06-26 | 安杰斯制药公司 | Macrocyclic compounds as TRK kinase inhibitors and uses thereof |
CN110950889A (en) * | 2018-09-27 | 2020-04-03 | 北京赛林泰医药技术有限公司 | Multi-target kinase inhibitor and preparation method and application thereof |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113332328A (en) * | 2021-06-07 | 2021-09-03 | 山东省千佛山医院 | Medicine for diseases of respiratory and endocrinology departments |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105960405B (en) | Glutaminase inhibitors | |
CN111039942B (en) | Nitrogen-containing heterocyclic compound, and preparation method, pharmaceutical composition and application thereof | |
WO2020259432A1 (en) | Kras-g12c inhibitor | |
CN110582500B (en) | Bicyclic nucleocapsid inhibitors and their use as medicaments for the treatment of hepatitis b | |
WO2023036285A1 (en) | Heteroaromatic compound and application thereof | |
KR102238012B1 (en) | Carboline derivatives, bromodomain inhibitors | |
EP2621491B1 (en) | 2-pyridone antimicrobial compositions | |
CN116249683A (en) | Deuteromethyl substituted pyrazinopyrazinoquinolinone derivative, preparation method and application thereof in medicine | |
CN111925368B (en) | Pyrimidone derivatives, preparation method thereof and application thereof in resisting mycobacterium tuberculosis infection | |
EP4077324A1 (en) | Novel compounds and their use | |
CN113072564A (en) | Heteroaromatic ring compound and application thereof | |
CN112457308A (en) | Novel tricyclic aromatic heterocyclic compound, and preparation method, pharmaceutical composition and application thereof | |
KR102485731B1 (en) | JAK Enzyme Inhibitors and Manufacturing Methods and Uses Thereof | |
CZ289268B6 (en) | Camptothecin derivatives, process of their preparation and pharmaceutical preparation in which they are comprised | |
CN113637013A (en) | Preparation and application of biaryl ring linked aromatic heterocyclic derivative as immunomodulator | |
KR102650441B1 (en) | Internally cyclic sulfiamidine amide-aryl amide compounds and their use for the treatment of hepatitis B | |
EP3932915A1 (en) | Acryloyl-containing nuclear transport regulator and uses thereof | |
WO2021047553A1 (en) | Aromatic heterocyclic compound having tricyclic structure, and preparation method therefor and application thereof | |
CN113929676A (en) | Pyridino-heterocyclic derivative and preparation method and application thereof | |
CN116217556A (en) | Polycyclic nonene compound and preparation method and application thereof | |
CN109956986A (en) | Liver delivers gemcitabine pro-drug nucleosides cyclic phosphate compound and application | |
CN112851561A (en) | NR6A1 protein receptor inhibitor and preparation and application thereof | |
CN112876352A (en) | GPR120 protein receptor inhibitor and preparation and application thereof | |
CN106810553B (en) | 3- (4, 5-substituted aminopyrimidine) phenyl derivative and application thereof | |
CN112300247A (en) | Teixobactin analogue and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210706 |